TY - JOUR
T1 - Weight loss, the gut and the inflammatory response in AIDS patients
AU - Stein, T. P.
AU - Koerner, B.
AU - Schluter, M. D.
AU - Leskiw, M. J.
AU - Gaprindachvilli, T.
AU - Richards, E. W.
AU - Cope, F. O.
AU - Condolucci, D.
N1 - Funding Information:
Supported by NIH grant NIADDK 07464 and Ross Products Division of Abbott Laboratories[
PY - 1997/2
Y1 - 1997/2
N2 - The objective of this study was to test the hypothesis that the integrity of the large bowel wall in AIDS patients is compromised in a manner that favours the chronic translocation of bacteria and/or products of bacterial metabolism into the bloodstream. When such translocation occurs, it induces a characteristic stress/inflammatory response in the body. Urinary butyrate, a unique product of colonic microbial metabolism, was used to assess gut wall permeability. Excretion of the pro-inflammatory cytokine IL-6 in the urine was used as a marker for the stress/inflammatory response. Four groups of subjects were studied, controls (n = 12), HIV+ (n = 35) and AIDS patients with (n = 14) and without (n = 17) weight loss. Results: measurable amounts of interleukin 6 (IL-6) and butyrate were found in the urine of all subjects. There were no significant differences in IL-6 excretion between the controls (0.68 ± 0.64 pg/ml), asymptomatic HIV+ subjects (0.59 ± 0.37 pg/ml) and AIDS patients without weight loss (1.18 ± 0.33 pg/ml) but IL-6 levels were significantly higher in the AIDS group with weight loss (4.02 ± 1.26 pg/ml, P < 0.05). A similar pattern of results was found with interleukin 1 receptor antagonist (IL-1ra). Like IL-6 and (IL-1ra), urinary butyrate levels were increased in the AIDS patients with weight loss (2.83 ± 0.67 μmol/l) relative to the controls (1.31 ± 0.13 μmol/l, P < 0.05), with the HIV+ patients (1.65 ± 0.18 μmol/l) and AIDS patients without weight loss (1.90 ± 0.22 μmol/l) falling in between. The data are consistent with a low, but chronic rate of bacteria and/or bacterial products seeping across a compromised colonic wall causing a chronic low stress response in AIDS patients.
AB - The objective of this study was to test the hypothesis that the integrity of the large bowel wall in AIDS patients is compromised in a manner that favours the chronic translocation of bacteria and/or products of bacterial metabolism into the bloodstream. When such translocation occurs, it induces a characteristic stress/inflammatory response in the body. Urinary butyrate, a unique product of colonic microbial metabolism, was used to assess gut wall permeability. Excretion of the pro-inflammatory cytokine IL-6 in the urine was used as a marker for the stress/inflammatory response. Four groups of subjects were studied, controls (n = 12), HIV+ (n = 35) and AIDS patients with (n = 14) and without (n = 17) weight loss. Results: measurable amounts of interleukin 6 (IL-6) and butyrate were found in the urine of all subjects. There were no significant differences in IL-6 excretion between the controls (0.68 ± 0.64 pg/ml), asymptomatic HIV+ subjects (0.59 ± 0.37 pg/ml) and AIDS patients without weight loss (1.18 ± 0.33 pg/ml) but IL-6 levels were significantly higher in the AIDS group with weight loss (4.02 ± 1.26 pg/ml, P < 0.05). A similar pattern of results was found with interleukin 1 receptor antagonist (IL-1ra). Like IL-6 and (IL-1ra), urinary butyrate levels were increased in the AIDS patients with weight loss (2.83 ± 0.67 μmol/l) relative to the controls (1.31 ± 0.13 μmol/l, P < 0.05), with the HIV+ patients (1.65 ± 0.18 μmol/l) and AIDS patients without weight loss (1.90 ± 0.22 μmol/l) falling in between. The data are consistent with a low, but chronic rate of bacteria and/or bacterial products seeping across a compromised colonic wall causing a chronic low stress response in AIDS patients.
UR - http://www.scopus.com/inward/record.url?scp=0031081632&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031081632&partnerID=8YFLogxK
U2 - 10.1006/cyto.1996.0148
DO - 10.1006/cyto.1996.0148
M3 - Article
C2 - 9071566
AN - SCOPUS:0031081632
SN - 1043-4666
VL - 9
SP - 143
EP - 147
JO - Cytokine
JF - Cytokine
IS - 2
ER -